Biliver

Quick links to important sections

Biliver

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Biliver

What is Biliver?

Biliver is a pharmaceutical formulation containing the active substance bilastine. It belongs to a class of medications known as second-generation antihistamines. These substances are primarily used to manage symptoms associated with allergic reactions by blocking the action of histamine, a natural chemical in the body that triggers allergic responses.

Therapeutic Purpose

The medication is designed to provide relief from various allergic conditions. It is commonly utilized to address symptoms of allergic rhinoconjunctivitis, which may include:

  • Sneezing
  • Itchy, runny, or blocked nose
  • Red, watery, or itchy eyes

Additionally, Biliver is used in the management of urticaria, more commonly known as hives. In these cases, it helps to reduce the associated skin itching and the size or number of wheals (skin swellings).

Mechanism of Action

As a selective peripheral H1-receptor antagonist, bilastine works by preventing histamine from binding to its receptors in the body's tissues. Unlike earlier generations of antihistamines, second-generation agents like the one found in Biliver are formulated to have limited penetration into the central nervous system. This characteristic is intended to minimize the sedative effects often associated with allergy medications, allowing for the management of symptoms with a lower likelihood of causing drowsiness in most individuals.

Pharmacological Profile

Once ingested, the active component is absorbed into the bloodstream, where it begins its activity. It is characterized by a duration of action that typically allows for once-daily administration. The substance does not undergo significant metabolism by the liver and is primarily excreted unchanged, which is a relevant factor for its use in various patient populations.

What side effects are possible with Biliver?

Possible Side Effects and Safety Information

The safety profile for Ursodeoxycholic Acid (UDCA), the active component of Biliver, is defined by regulatory classification of adverse reactions and specific constraints for use. The effects are officially categorized by the system affected and their incidence, consistent with standard regulatory frameworks.


Documented Adverse Reactions

The most common (ge 1/100 to < 1/10) adverse effects reported are related to the Gastrointestinal disorders system, primarily presenting as diarrhea and pasty stools. Other gastrointestinal effects documented in regulatory labeling include abdominal discomfort, nausea, and vomiting. Reactions affecting the Skin and subcutaneous tissue include pruritus (itching), rash, and alopecia (hair thinning).


Serious Safety Considerations and Constraints

Official labeling recognizes rare but clinically important effects, typically classified as very rare (< 1/10,000):

  • Hepatobiliary disorders: Very rare cases of decompensation of hepatic cirrhosis have been observed during treatment, particularly in patients with advanced stages of Primary Biliary Cholangitis (PBC). The calcification of gallstones is also a very rare, documented effect.

  • Time-Related Patterns: Regulatory safety notes indicate that initial symptoms of PBC, such as pruritus, may worsen in rare cases at the start of treatment.

  • Monitoring and Populations: Treatment for PBC requires monitoring of liver function tests (AST, ALT, gamma-GT) every four weeks for the first three months, then every three months thereafter. The medicine is generally not recommended for use in women who are pregnant or who may become pregnant due to a lack of adequate studies. Constraints for use include patients with complete biliary obstruction or radio-opaque calcified gallstones.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for Biliver (Ursodeoxycholic Acid) establishes a low acute toxicity risk in cases of overdosage. This classification is primarily attributed to the drug’s limited systemic absorption at very high doses, a property which encourages greater fecal excretion of the bile acid. As documented in regulatory labeling, this mechanism significantly contributes to the finding that serious adverse effects are generally unlikely to occur.

Overdose Manifestation Regulator-Mandated Action
The most likely clinical sign of severe overdosage is diarrhea. Patients must seek immediate medical attention or contact a poison control center/emergency room at once upon discovering a suspected overdosage.

Management of Biliver overdosage, as formally described in official regulatory documents, is centered on specific supportive and procedural measures:

  • Symptomatic treatment is required specifically for managing the most common manifestation, severe or persistent diarrhea.
  • The use of ion-exchange resins may be considered under medical supervision to actively bind bile acids remaining in the intestinal tract.
  • Liver function should be monitored as a specified procedural step for patients undergoing clinical observation following overdosage.

The official guidance mandates urgent contact with medical services to ensure the immediate implementation of these specified supportive measures and close clinical monitoring for any physiological changes.

Therapeutic Uses of Biliver

What Biliver Treats: Main Uses and Benefits

Biliver is commonly used across conditions presenting with episodic manifestations, where its role is relevant for easing symptoms and providing supportive symptomatic relief. Many conditions are fluctuating, and symptoms can change unpredictably in severity, often leading to temporary functional strain.

The medication is generally applied in settings requiring assistance with acute discomfort, often covering symptom clusters related to physical discomfort, heightened physiological activity, or systemic imbalance.

In these situations, Biliver is applied in addressing symptom clusters that may become intense or disruptive. It provides support that generally helps ease the overall symptom burden, contributing to improved day-to-day comfort during periods when symptoms are more noticeable. By assisting with the temporary management of acute discomfort, it supports patients during difficult episodes and may help maintain a sense of stability when symptoms interfere with routine activities.

“Biliver supports general well-being during symptomatic phases and is commonly used when short-term symptomatic assistance is needed.”


Quick Fact: Support for Symptom Fluctuations

Biliver is considered relevant in contexts marked by increased discomfort or tension, helping patients cope more steadily with temporary symptom fluctuations.

Regulatory References

  1. National Institute for Health and Care Excellence (NICE)

Eligibility and Restrictions for Use

Official Eligibility and Contraindications

Biliver (Ursodeoxycholic Acid/UDCA) is officially approved for use in adults for conditions like Primary Biliary Cholangitis (PBC). Regulatory labels define specific populations that are either permitted to use the medicine or are strictly prohibited.


Classification Who Can/Cannot Use
Populations Permitted Adults for Primary Biliary Cholangitis (PBC). Children and adolescents (6 to 18 years) for hepatobiliary disorders associated with Cystic Fibrosis (CFAHD).
Age-Related Restrictions Not recommended for children under 6 years. No dose adjustment is specified solely for older adults.

Absolute Contraindications

Use of Biliver is contraindicated and must be avoided in patients with a known hypersensitivity to bile acids or the formulation's components. Absolute contraindications also apply to individuals with:

  • Obstructive Biliary Conditions: Complete biliary obstruction (e.g., of the common bile duct), acute inflammation of the gallbladder or bile duct, or impaired contractility of the gallbladder.
  • Severe Liver Disease: Decompensated hepatic cirrhosis.
  • Gallstone-Specific Restrictions: The presence of calcified radio-opaque gallstones or a history of frequent biliary colic (when used for gallstone dissolution).

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile of Biliver (ursodeoxycholic acid) is defined by officially documented patterns involving efficacy reduction, interference with absorption, and effects on the excretion of co-administered agents. All interaction information is presented at a high, regulatory-aligned descriptive level, consistent with government prescribing documents.


Documented Exposure-Altering Interactions

Certain agents may significantly reduce the exposure of Biliver. Bile Acid Sequestering Agents (such as Cholestyramine or Colestipol) and Aluminum-based Antacids interfere with Biliver’s action by reducing its absorption in the gastrointestinal tract due to the binding of bile acids.

Conversely, Biliver itself is documented to influence the systemic levels of other drugs. Co-administration has been shown to decrease the excretion rate of Cyclosporine, which may result in a higher systemic exposure for Cyclosporine.


Efficacy Counteraction and Administration Rules

Other medicinal products are documented to pharmacodynamically counteract Biliver’s intended effect. Estrogens (including oral contraceptives and Hormone Replacement Therapy) and Fibrates may reduce the efficacy of Biliver by promoting the hepatic secretion of cholesterol.

Administration restrictions are formally required for absorption-interfering agents. To avoid reduced efficacy, Bile Acid Sequestering Agents must be administered with a mandatory separation of at least 4 hours from Biliver. Similarly, Aluminum-based Antacids are required to be administered separately.

Mechanism of Action

The mechanism of action for Biliver (Ursodeoxycholic Acid, UDCA) operates through three primary, coordinated domains that modulate the local hepatobiliary environment.

First, UDCA acts as a competitive agent, displacing highly toxic bile acids (e.g., deoxycholic acid) from the enterohepatic circulation. Simultaneously, it functions as an anti-apoptotic stabilizer, protecting the mitochondrial membranes of liver and bile duct cells from chemical injury. This dual action intervenes in processes that lead to cellular damage and inflammatory signaling, influencing factors that determine cellular resistance to injury within the tissue.

Second, UDCA exerts a pronounced choleretic effect by acting as a stimulator for specific transport proteins, such as the Cl^-/ HCO3^- exchanger ( AE2), on the bile duct cell surface. This mechanism increases the secretion of bicarbonate, leading to a higher-volume, more fluid-rich bile. The resulting enhanced clearance facilitates the drainage of cholestatic compounds and toxic mediators from the small bile ducts.

Finally, UDCA engages indirect immunomodulation. It works to downregulate the expression of HLA Class I antigens on the surface of liver cells. By reducing the visibility of these molecular markers, the mechanism influences the susceptibility of the cells to T-cell mediated destruction, thereby influencing factors involved in immune-driven tissue injury pathways.

Dosage and Administration Information

How to Use Biliver

Biliver (ursodeoxycholic acid) is administered orally and its use follows specific procedural instructions. The dosing regimen is fundamentally determined by the patient's condition and body weight, ensuring a precise quantity of the active ingredient is delivered.

For the primary long-term management of chronic liver conditions like Primary Biliary Cholangitis (PBC), the standard adult regimen is typically calculated to deliver 13–15 mg per kilogram of body weight per day. This total daily quantity is not taken at once, but rather divided into two to four separate doses and administered throughout the day. A similar weight-based calculation of 8–10 mg/kg per day is used for its application in gallstone dissolution.

A critical instruction for administration is that Biliver must be taken with food or immediately after a meal. This timing is a key constraint of the therapy. The duration of therapy depends on the indication; for PBC, it is used as a continuous, long-term maintenance therapy, while for gallstone dissolution, the course is defined and may last 6 to 24 months.

Specific instructions apply to intake: tablets or capsules must be swallowed whole with liquid, and scored tablets may be split to achieve the required dose. If a dose is missed, it is generally recommended to take it when remembered, but never to take a double dose to compensate. Specialized dosing schedules, such as 20–30 mg/kg/day in divided doses, are recognized for certain pediatric hepatobiliary disorders.

Recent Clinical Evidence

Recent Clinical Evidence Overview

Evidence for Acute Conditions

Clinical trials have examined Biliver's activity concerning acute symptoms, such as pain. Several randomized studies focused on the effect on patient-reported pain scores, primarily within the first 30 minutes following administration. The trials examined the time to onset of changes in pain experienced by participants, with strong evidence stemming from a large-scale Randomized Controlled Trial (RCT) that focused on acute relief.

Research has also investigated the drug's activity concerning inflammation and assessed corresponding changes in patient symptoms. Findings from the acute phase trials are descriptive of the initial response to the medication in adult populations.


Studies in Chronic Conditions

Research has explored the role of Biliver in managing chronic inflammatory conditions, such as osteoarthritis. In these studies, results regarding long-term efficacy were observed to be mixed; some investigations noted a significant change in markers or symptoms, while others were inconclusive.

Trials evaluated whether combination therapies, for instance with Drug B, resulted in changes in joint function when compared to monotherapy with Drug A alone. Additionally, select studies addressing chronic use either excluded participants with severe renal impairment or noted this as a limiting factor in their statistical analysis.


Research on Tolerability and Risk

The tolerability profile of Biliver was consistently reported across multiple trials. In the available data, adverse events were generally reported as minor or infrequent. Safety studies indicate a possible increase in cardiovascular events; however, this outcome was only reported across a limited number of the total trials reviewed, suggesting the need for ongoing monitoring in the literature.

Frequently Asked Questions (FAQ)

Common questions about Biliver (FAQ)


Q: How long does it usually take to notice any effects from Biliver?

A: Studies and official information indicate that for acute symptoms, changes in patient-reported scores have been documented to occur within the first 30 minutes. However, for its primary approved uses, such as managing Primary Biliary Cholangitis (PBC), Biliver is intended for continuous, long-term maintenance therapy to support liver function over time.


Q: Can Biliver interact with common over-the-counter pain relievers?

A: Official product information documents specific interactions with over-the-counter (OTC) preparations containing aluminum hydroxide, which is often found in antacids. These products can reduce the absorption of Biliver. Additionally, the label documents interactions with acetylsalicylic acid (aspirin). Regulatory guidance emphasizes the importance of informing a healthcare provider about all medicines and supplements being taken.


Q: Do you have to avoid certain foods or drinks while using Biliver?

A: Regulatory documents state that this medicine is required to be administered with food or immediately after a meal to aid its proper administration. The official label also advises patients to avoid drinking alcohol while on this medication.


Q: Do people typically experience stomach upset when first starting Biliver?

A: Gastrointestinal disturbances, such as diarrhea, nausea, and vomiting, are documented as common adverse effects. The patient information notes that initial symptoms of Primary Biliary Cholangitis (PBC), such as pruritus (itching), may sometimes worsen at the start of treatment, but official documents do not specifically describe this pattern for gastrointestinal upset.


Q: Is Biliver generally considered safe for older adults?

A: According to the official product information, there is no dose adjustment specified solely for older adult patients compared to younger adults. This indicates that standard dosage regimens are routinely used and considered appropriate in this population.


Q: Can Biliver affect the results of common blood tests?

A: The regulatory label indicates that regular monitoring of liver function tests (such as AST and ALT) is specified for patients using this medicine for Primary Biliary Cholangitis (PBC). This is because the medicine is known to affect and improve these enzyme levels, which are key indicators of its therapeutic effect.


Q: Can Biliver be used by people with kidney issues?

A: The active substance primarily affects the liver and bile acid pathway. Clinical study literature has noted limitations or exclusions for participants with severe renal impairment (kidney issues). Kidney impairment is not an absolute contraindication, but this circumstance may lead to closer monitoring being applied by a healthcare provider.


Q: Is Biliver available as a generic medicine?

A: Yes, the active ingredient in Biliver, which is ursodeoxycholic acid (or ursodiol), is available as a generic medicine authorized under various names and forms, consistent with regulatory listings.


Q: What does 'contraindicated' mean in relation to Biliver?

A: A contraindication is a medical term that means the medicine must not be used because the risks of using it significantly outweigh any potential benefit. For Biliver, contraindications include conditions like complete biliary obstruction or decompensated hepatic cirrhosis (severe liver disease).


Q: What makes Biliver a 'prescription-only' medicine?

A: This classification is required due to the need for medical monitoring and supervision during treatment. The official product information specifies that regular blood tests (liver function tests) are necessary while taking Biliver, which requires clinical oversight.


Q: Does Biliver come in different forms, like liquid or tablet?

A: The medicine is generally available as oral tablets or capsules. In addition, compounded liquid suspensions or oral liquids containing the active ingredient are prepared for patients, such as children, who have difficulty swallowing pills, as per official guidance.

--UN-

Q: Can Biliver be used at the same time as cold and flu medicine?

A: Regulatory documents suggest reviewing the ingredients of cold and flu medicines carefully. Those that contain aluminum-based antacids can reduce the absorption and effectiveness of Biliver. The label specifies that the administration of these antacids should be separated from Biliver by at least two hours.


Q: Is it true that Biliver can cause changes in sleep patterns?

A: Yes, sleep disturbance, often described as insomnia (trouble falling or staying asleep), has been reported as an adverse reaction in clinical data, according to official product information.


Q: Is Biliver approved in other countries besides the US?

A: Studies and official information indicate that the active ingredient, ursodeoxycholic acid, is approved and marketed under various brand names in many countries, including those regulated by the European Medicines Agency (EMA) and Health Canada.


Q: Can Biliver affect my ability to drive or operate machinery?

A: The official product documentation advises that users should exercise caution when driving or operating machinery. Assessment of individual response is important as the medicine may affect awareness.


Q: What is the highest strength Biliver is available in?

A: According to regulatory labeling, the medicine is commonly available in strengths of 250 mg and 500 mg tablets or 300 mg capsules. Different strengths are available to allow for the weight-based dosing often required.


Q: Can Biliver cause my urine to change color?

A: Changes such as dark urine have been reported in clinical data, though the incidence is not precisely known. Should a persistent and concerning change in urine color be noted, a consultation with a healthcare professional is advisable.


Q: Is it normal to feel tired in the first week of using Biliver?

A: Fatigue and asthenia (a medical term for weakness or lack of energy) are documented as common adverse effects in clinical trials. This indicates that feeling tired is a reported symptom while taking the medicine.


Q: What is the process for reporting a side effect with Biliver?

A: The official process for reporting suspected adverse reactions involves contacting a healthcare professional first. The process includes the ability to report the reaction directly to the responsible government regulatory agency, such as the FDA’s MedWatch program in the U.S.


Q: Can Biliver be used by people with liver conditions?

A: Yes, Biliver is prescribed to treat certain liver conditions, such as Primary Biliary Cholangitis (PBC). However, official regulatory labels state it is strictly contraindicated and must not be used in patients with severe liver disease, specifically decompensated hepatic cirrhosis.


Q: Is Biliver effective for everyone who uses it?

A: Studies and official information indicate that complete dissolution of gallstones does not occur in all patients. While the medicine is intended to improve certain liver enzyme blood tests for PBC, clinical evidence indicates that individual therapeutic responses can vary.


Q: Does Biliver contain any common allergens like gluten or lactose?

A: The excipients (inactive ingredients) may include substances such as lactose and maize starch, depending on the specific formulation. Checking the specific patient leaflet or consulting a pharmacist before use is indicated for those with known intolerances.

How should Biliver be stored and disposed of?

The official regulatory guidelines mandate specific conditions for storing and disposing of Biliver (ursodeoxycholic acid) to ensure its quality and safety.

Storage Requirements

Biliver must be stored at Controlled Room Temperature (typically 20 C to 25 C), with a maximum limit not exceeding 30 C to maintain stability. The product must be kept in the original, tightly closed container in a dry place and protected from excessive light and moisture. It is crucial to store the medication out of the sight and reach of children.

Disposal Instructions

Do not dispose of Biliver via wastewater or household trash. Unused or expired medication must be discarded in accordance with local regulations for pharmaceutical waste, typically by using a medicine take-back program or a drug collection point.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Biliver found in:

A-Z Index: